<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="6.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Murugesan, Gavuthami</style></author><author><style face="normal" font="default" size="100%">Correia, Viviana G.</style></author><author><style face="normal" font="default" size="100%">Palma, Angelina S.</style></author><author><style face="normal" font="default" size="100%">Chai, Wengang</style></author><author><style face="normal" font="default" size="100%">Li, Chunxia</style></author><author><style face="normal" font="default" size="100%">Feizi, Ten</style></author><author><style face="normal" font="default" size="100%">Martin, Eva</style></author><author><style face="normal" font="default" size="100%">Laux, Brigitte</style></author><author><style face="normal" font="default" size="100%">Franz, Alexandra</style></author><author><style face="normal" font="default" size="100%">Fuchs, Klaus</style></author><author><style face="normal" font="default" size="100%">Weigle, Bernd</style></author><author><style face="normal" font="default" size="100%">Crocker, Paul R</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Siglec-15 recognition of sialoglycans on tumor cell lines can occur independently of sialyl Tn antigen expression.</style></title><secondary-title><style face="normal" font="default" size="100%">Glycobiology</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2020</style></year><pub-dates><date><style  face="normal" font="default" size="100%">may</style></date></pub-dates></dates><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;Siglec-15 is a conserved sialic acid-binding Ig-like lectin expressed on osteoclast progenitors that plays an important role in osteoclast development and function. It is also expressed by tumor-associated macrophages and by some tumors, where it is thought to contribute to the immunosuppressive microenvironment. It was shown previously that engagement of macrophage-expressed Siglec-15 with tumor cells expressing its ligand, sialyl Tn (sTn), triggered production of TGF-$\beta$. In the present study, we have further investigated the interaction between Siglec-15 and sTn on tumor cells and its functional consequences. Based on binding assays with lung and breast cancer cell lines and glycan-modified cells, we failed to see evidence for recognition of sTn by Siglec-15. However, using a microarray of diverse, structurally-defined glycans, we show that Siglec-15 binds with higher avidity to sialylated glycans other than sTn or related antigen sequences. In addition, we were unable to demonstrate enhanced TGF-$\beta$ secretion following co-culture of Siglec-15-expressing monocytic cells lines with tumor cells expressing sTn, or following Siglec-15 cross-linking with monoclonal antibodies. However, we did observe activation of the SYK/MAPK signaling pathway following antibody cross-linking of Siglec-15 that may modulate the functional activity of macrophages.&lt;/p&gt;
</style></abstract><notes><style face="normal" font="default" size="100%">&lt;p&gt;n/a&lt;/p&gt;
</style></notes></record></records></xml>